BACKGROUND AND PURPOSE: Thromboembolism is a recognized complication occurring
during endovascular coil embolization of intracranial aneurysms. Recently, there has been …

Background Experience with intra-arterial infusion of abciximab for the treatment of
endovascular thrombotic complications is limited to short case series. Our objective is to …

BACKGROUND: Thromboembolic complications are the most common cause of
periprocedural morbidity associated with the endovascular treatment of intracranial …

Introduction Thrombotic events are a common and severe complication of endovascular
aneurysm treatment with significant impact on patients' outcome. This study evaluates risk …

BACKGROUND AND PURPOSE: Experience with intravenous abciximab to manage
thromboembolism during treatment of ruptured intracranial aneurysms is limited. We present …

Background and purpose Thrombus formation during endovascular embolization of
intracranial aneurysms occurs in 2.9%–6% of patients. Use of IIb/IIIA inhibitors such as …

BACKGROUND AND PURPOSE: Abciximab and tirofiban are commonly used for the
treatment of thromboembolisms that form during coiling of intracranial aneurysms; however …

BACKGROUND AND PURPOSE: Platelet-derived thrombi may occur during intracranial
aneurysm coiling. We report a series of 13 patients treated with intraarterial Abciximab for …

Background and Purpose—The purpose of this study was to estimate the safety and efficacy
of abciximab treatment in combination with prophylactic heparin, acetylsalicylic acid (ASA) …

Object Experience with intraarterial abciximab for the treatment of thromboembolism during
endovascular coil embolization is limited. The authors report the outcome of intraarterial …